# Danish company LEO Pharma is stepping up its dermatological game by acquiring U.S. drug developer Replay for $50 million upfront.

*biotech · news · 2026-05-02 · Devdiscourse*

## Key points

- LEO Pharma is acquiring U.S. drug developer Replay for $50 million upfront.
- The LEO Pharma acquisition aims to enhance treatments for rare genetic skin diseases.
- Bristol Myers Squibb's quarterly revenue reached $11.49 billion, surpassing Wall Street expectations.
- Cardinal Health's shares fell 8% after third-quarter revenue missed estimates, partly due to Inflation Reduction Act regulations.

**Companies:** Bristol Myers Squibb, LEO Pharma, Cardinal Health
**Countries:** Denmark, United States

[Read the full story on Devdiscourse](https://www.devdiscourse.com/article/health/3893919-global-health-developments-deals-dramatics-and-discoveries)

---

Canonical: https://newsio.io/n/e2c9bcdd-d611-4e14-b7a4-f867533b845b/danish-company-leo-pharma-is-stepping-up-its-dermatological-game-by-acquiring-u
Summarized by Newsio from Devdiscourse. https://newsio.io/how-it-works